New Results
Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
Daniel J. Sheward, Changil Kim, Roy A. Ehling, Alec Pankow, View ORCID ProfileXaquin Castro Dopico, Darren Martin, Sai Reddy, Joakim Dillner, Gunilla B. Karlsson Hedestam, Jan Albert, Ben Murrell
doi: https://doi.org/10.1101/2021.12.19.473354
Daniel J. Sheward
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
2Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa
Changil Kim
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
Roy A. Ehling
3Department of Biosystems Science and Engineering, ETH Zürich
Alec Pankow
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
Xaquin Castro Dopico
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
Darren Martin
2Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa
Sai Reddy
3Department of Biosystems Science and Engineering, ETH Zürich
Joakim Dillner
4Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden
Gunilla B. Karlsson Hedestam
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
Jan Albert
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
5Dept of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden
Ben Murrell
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Article usage
Posted December 20, 2021.
Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
Daniel J. Sheward, Changil Kim, Roy A. Ehling, Alec Pankow, Xaquin Castro Dopico, Darren Martin, Sai Reddy, Joakim Dillner, Gunilla B. Karlsson Hedestam, Jan Albert, Ben Murrell
bioRxiv 2021.12.19.473354; doi: https://doi.org/10.1101/2021.12.19.473354
Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
Daniel J. Sheward, Changil Kim, Roy A. Ehling, Alec Pankow, Xaquin Castro Dopico, Darren Martin, Sai Reddy, Joakim Dillner, Gunilla B. Karlsson Hedestam, Jan Albert, Ben Murrell
bioRxiv 2021.12.19.473354; doi: https://doi.org/10.1101/2021.12.19.473354
Subject Area
Subject Areas
- Biochemistry (9128)
- Bioengineering (6774)
- Bioinformatics (23989)
- Biophysics (12117)
- Cancer Biology (9523)
- Cell Biology (13773)
- Clinical Trials (138)
- Developmental Biology (7627)
- Ecology (11686)
- Epidemiology (2066)
- Evolutionary Biology (15506)
- Genetics (10638)
- Genomics (14322)
- Immunology (9479)
- Microbiology (22832)
- Molecular Biology (9089)
- Neuroscience (48981)
- Paleontology (355)
- Pathology (1480)
- Pharmacology and Toxicology (2568)
- Physiology (3844)
- Plant Biology (8327)
- Synthetic Biology (2296)
- Systems Biology (6187)
- Zoology (1300)